Scarica l'app Stockscreener
54.09
1.88%
1.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$53.09
Aprire:
$54.41
Volume 24 ore:
1.94M
Relative Volume:
1.14
Capitalizzazione di mercato:
$5.33B
Reddito:
$4.10M
Utile/perdita netta:
$-568.53M
Rapporto P/E:
-8.7076
EPS:
-6.2118
Flusso di cassa netto:
$-401.18M
1 W Prestazione:
+7.68%
1M Prestazione:
+11.39%
6M Prestazione:
-1.37%
1 anno Prestazione:
+21.74%
Intervallo 1D:
$53.02
$55.79
Intervallo di 1 settimana:
$49.71
$55.79
Portata 52W:
$43.23
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
54.09 | 5.33B | 4.10M | -568.53M | -401.18M | -6.2118 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | JP Morgan | Overweight |
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
CRISPR Therapeutics StockWeekly review against gene-editing peers - AD HOC NEWS
CRISPR Therapeutics AG (CRSP) is a trending stock: Facts to know before betting on it - MSN
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year - The Motley Fool
CRISPR Therapeutics AG (CRSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRISPR Therapeutics AG (CRSP) Institutional Confidence - TradingKey
CRISPR Therapeutics AG (CRSP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CRISPR Therapeutics AG (CRSP) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
The Best Biotech Stocks to Buy in 2026 - The Motley Fool
symbol__ Stock Quote Price and Forecast - CNN
CRISPR Therapeutics AG (CRSP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Is CRISPR Therapeutics’ (CRSP) ESOP Shelf Registration Quietly Redefining Its Long‑Term Risk‑Reward Profile? - simplywall.st
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know - MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Why is CRISPR Therapeutics (CRSP) down 0.7% since last earnings report? - MSN
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Eastern Progress
Understanding the Setup: (CRSP) and Scalable Risk - Stock Traders Daily
28,037 Shares in CRISPR Therapeutics AG $CRSP Bought by Blue Jean Financial LLC - MarketBeat
CRISPR Therapeutics stock is absurdly cheap -- here's why analysts see 437% upside potential - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Citizens reiterates CRISPR Therapeutics stock rating on Casgevy data By Investing.com - Investing.com Australia
Citizens reiterates CRISPR Therapeutics stock rating on Casgevy data - Investing.com
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE) - The Globe and Mail
CRISPR Therapeutics AG (CRSP) advances but underperforms market: Key facts - MSN
CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know - MSN
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts - Yahoo Finance
Crispr Therapeutics AG (CRSP) Gets a Buy from Mizuho Securities - The Globe and Mail
Why is Crispr Therapeutics stock gaining 3% today? By Investing.com - Investing.com Nigeria
Why is Crispr Therapeutics stock gaining 3% today? - Investing.com UK
Morgan Stanley assumes CRISPR Therapeutics stock with equalweight rating - Investing.com
Morgan Stanley assumes CRISPR Therapeutics stock with equalweight rating By Investing.com - Investing.com Canada
CRISPR Therapeutics AG Stock 12‑Month Price Target Cut to $81.1, Implies 64% Upside - TradingView
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know - MSN
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Norges Bank Buys Shares of 490,206 CRISPR Therapeutics AG $CRSP - MarketBeat
Amova Asset Management Americas Inc. Sells 205,564 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
[Form 4] CRISPR Therapeutics AG Insider Trading Activity - Stock Titan
Director at CRISPR (CRSP) receives 13,000-share stock option grant - Stock Titan
CRISPR Therapeutics (CRSP) director granted 13,000 options at $51.84 strike - Stock Titan
CRISPR Therapeutics (CRSP) director awarded 13,000-share stock option grant - Stock Titan
Transcript : CRISPR Therapeutics AG Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02 - marketscreener.com
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? - AOL.com
CRISPR Therapeutics stock (CH0334081137): Gene-editing hopes after recent updates on exa-cel and pip - AD HOC NEWS
CRISPR Therapeutics Faces Stagnant Stock Despite Promising Pipeline - Intellectia AI
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? - The Motley Fool
Eli Lilly just proved gene editing could be pharma's next gold rush -- but CRISPR Therapeutics investors should watch out - MSN
Contrarius Group Holdings Ltd Has $8.21 Million Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Capital International Investors Increases Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Why CRISPR Therapeutics (CRSP) Is Down 7.7% After Major Shelf Filing and Governance Changes – And What's Next - simplywall.st
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):